{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"5.6"},{"groupId":"OG002","value":"15.6"},{"groupId":"OG003","value":"8.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"495"}],"units":"Participants"}],"description":"Per planned analysis, populations to be used for evaluation of this outcome measure were as follows: Triple Negative Breast Cancer (TNBC) Target Population, HR+/HER2- Metastatic Breast Cancer (mBC) Population, Metastatic Urothelial Cancer (mUC) Population, and Overall Safety Population (OSP).","groups":[{"description":"Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.","id":"OG000","title":"TNBC Target Population"},{"description":"Overall 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. Of these 68 participants, 54 were confirmed as HR+/HER2-, had progressed on at least one prior hormonal therapy in the metastatic setting, and had received at least one dose of 10 mg/kg SG. These 54 participants were included in the analysis of safety and were referred to as the HR+/HER2- mBC Population.","id":"OG001","title":"HR+/HER2- mBC Population"},{"description":"Overall 49 participants with metastatic urothelial cancer were enrolled in the study and received at least one dose of SG. Of these 49 participants, 45 had either relapsed after or were refractory to at least one prior standard therapeutic regimen and received at least one dose of 10 mg/kg SG. These 45 participants were included in the analysis of safety and were referred to as the mUC Population.","id":"OG002","title":"mUC Population"},{"description":"Overall 495 participants were enrolled in the study and received at least one dose of 10 mg/kg, 8 mg/kg, 12mg/kg, or 18mg/kg SG. These participants were included in the Overall Safety Population and analyzed for safety.","id":"OG003","title":"Overall Safety Population (OSP)"}],"paramType":"NUMBER","populationDescription":"* Target mTNBC: Participants with mTNBC who received at least 2 prior therapies for metastatic disease \\& who received at least 1 dose of 10 mg/kg SG\n* HR+/HER2-mBC: Participants with HR+/HER2- mBC who progressed on at least 1 prior hormonal therapy \\& who received at least 1 dose of 10 mg/kg SG\n* mUC: Participants who had relapsed after or were refractory to at least 1 prior treatments \\& who received at least 1 dose of 10 mg/kg SG\n* OSP: All participants who received at least 1 dose of SG","reportingStatus":"POSTED","timeFrame":"First dose date up to last dose for data cutoff date of 01 March 2019 (maximum duration: 55.2 months)","title":"Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}